Rapid diagnostic assay for the in-field identification of Coronaviruses including SARS-CoV-2 and the detection of mutations in its spike protein from human nasal, buccal or saliva samples. It can be used and easily read by individuals without medical expertise to provide integrated sample-to-answer in less than 30 minutes.
Primary Application Area: Biotech, Pharma, Health
Technology Development Status: Prototype
Technology Readiness Level: TRL 3
Organization Type: Mid-stage Startup (A or B)
GOVT/EXTERNAL FUNDING SOURCES